<?xml version="1.0" encoding="utf-8"?>
<iati-activities version="2.03" generated-datetime="2026-11-11T15:32:23+00:00">
  <iati-activity last-updated-datetime="2026-11-11T11:05:58+00:00" xml:lang="en" default-currency="USD" humanitarian="0" hierarchy="1">
    <iati-identifier>47045-ETH-Z-UNICEF-1</iati-identifier>
    <reporting-org ref="47045" type="30">
      <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
    </reporting-org>
    <title>
      <narrative>Emergency Funding to support procurement of essential commodities and services in conflict affected regions of Northern Ethiopia. - Ethiopia (01-Oct-2024-30-Sep-2025)</narrative>
    </title>
    <description type="1">
      <narrative>Ethiopia, Multicomponent, United Nations Children's Fund</narrative>
    </description>
    <description type="2">
      <narrative>Goal: To support critical emergency fund response in the conflict affected areas in Tigray, Amhara, Afar and Oromia, between October 2024 and September 2025. Objectives: To contribute to restoring TB, HIV and Malaria response in conflict affected areas in Northern Ethiopia; To complement the efforts of Federal Ministry of Health.</narrative>
    </description>
    <participating-org ref="47045" type="30" role="1" crs-channel-code="47045">
      <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
    </participating-org>
    <participating-org type="40" role="2" crs-channel-code="41000">
      <narrative>United Nations Children's Fund</narrative>
    </participating-org>
    <participating-org type="40" role="4" crs-channel-code="41000">
      <narrative>United Nations Children's Fund</narrative>
    </participating-org>
    <other-identifier ref="ETH-Z-UNICEFP01" type="A1">
      <owner-org ref="47045">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </owner-org>
    </other-identifier>
    <activity-status code="3" />
    <activity-date type="1" iso-date="2024-10-01" />
    <activity-date type="2" iso-date="2024-10-01" />
    <activity-date type="3" iso-date="2025-09-30" />
    <activity-date type="4" iso-date="2025-09-30" />
    <contact-info type="1">
      <organisation>
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </organisation>
      <department>
        <narrative>Communications</narrative>
      </department>
      <telephone>+41 58 791 1700</telephone>
      <email>website@theglobalfund.org</email>
      <website>https://www.theglobalfund.org</website>
      <mailing-address>
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland</narrative>
      </mailing-address>
    </contact-info>
    <contact-info type="2">
      <organisation>
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </organisation>
      <department>
        <narrative>Grant Management Division</narrative>
      </department>
      <person-name>
        <narrative>George Sakvarelidze</narrative>
      </person-name>
      <job-title>
        <narrative>Fund Portfolio Manager</narrative>
      </job-title>
      <telephone>+41 58 791 1700</telephone>
      <email>george.sakvarelidze@theglobalfund.org</email>
      <website>https://www.theglobalfund.org</website>
      <mailing-address>
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland</narrative>
      </mailing-address>
    </contact-info>
    <activity-scope code="4" />
    <recipient-country code="ET" percentage="100">
      <narrative>Ethiopia</narrative>
    </recipient-country>
    <sector vocabulary="1" code="12262" percentage="85.61">
      <narrative>Malaria</narrative>
    </sector>
    <sector vocabulary="1" code="12110" percentage="11.79">
      <narrative>Multicomponent, RSSH</narrative>
    </sector>
    <sector vocabulary="1" code="12263" percentage="2.6">
      <narrative>Tuberculosis</narrative>
    </sector>
    <tag vocabulary="2" code="3">
      <narrative>Ensure healthy lives and promote well-being for all at all ages</narrative>
    </tag>
    <tag vocabulary="3" code="3.3">
      <narrative>End the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases, and combat hepatitis, water-borne diseases and other communicable diseases</narrative>
    </tag>
    <tag vocabulary="3" code="3.8">
      <narrative>Achieve universal health coverage</narrative>
    </tag>
    <country-budget-items vocabulary="4">
      <budget-item code="be1b5900-2300-4fc2-b142-10ef3d0c2a60" percentage="1.18">
        <description>
          <narrative>Malaria -&gt; Case management -&gt; Epidemic preparedness</narrative>
        </description>
      </budget-item>
      <budget-item code="738953d0-45d2-486f-957e-e3fee8de75cd" percentage="11.75">
        <description>
          <narrative>Malaria -&gt; Case management -&gt; Facility-based treatment</narrative>
        </description>
      </budget-item>
      <budget-item code="c0797acd-77a1-43ee-9c39-6bf17fd6f4ed" percentage="24.29">
        <description>
          <narrative>Malaria -&gt; Case management -&gt; Integrated community case management (iCCM)</narrative>
        </description>
      </budget-item>
      <budget-item code="1c40e6d5-39ce-4815-b8c6-a88d14097c71" percentage="3.14">
        <description>
          <narrative>Malaria -&gt; Case management -&gt; Social and behavior change (SBC) (Case management)</narrative>
        </description>
      </budget-item>
      <budget-item code="0904e74b-3fd7-4544-bb4e-8343228bdbe5" percentage="45.25">
        <description>
          <narrative>Malaria -&gt; Vector control -&gt; Insecticide treated nets (ITNs) - Mass campaign: universal</narrative>
        </description>
      </budget-item>
      <budget-item code="43337786-bfab-487f-b388-9fbe8808948d" percentage="10.54">
        <description>
          <narrative>Multicomponent -&gt; Program management -&gt; Grant management</narrative>
        </description>
      </budget-item>
      <budget-item code="2c341d5c-b46c-47a9-9aff-2700be47f75e" percentage="1.26">
        <description>
          <narrative>RSSH -&gt; RSSH: Monitoring and evaluation systems -&gt; Analyses, evaluations, reviews and data use</narrative>
        </description>
      </budget-item>
      <budget-item code="1ed5e501-534e-43ae-bb9f-9552bd6bf461" percentage="2.59">
        <description>
          <narrative>Tuberculosis -&gt; Key and vulnerable populations (KVP) - TB/DR-TB -&gt; KVP - Mobile population (migrants/refugees/IDPs)</narrative>
        </description>
      </budget-item>
    </country-budget-items>
    <collaboration-type code="1" />
    <default-flow-type code="10" />
    <default-finance-type code="110" />
    <default-aid-type code="C01" vocabulary="1" />
    <default-tied-status code="5" />
    <budget type="2" status="2">
      <period-start iso-date="2024-01-01" />
      <period-end iso-date="2024-12-31" />
      <value currency="USD" value-date="2024-01-01">2543781.07</value>
    </budget>
    <capital-spend percentage="2.24" />
    <transaction ref="bf70e71f-cb59-4cff-9934-2c22f360e3a3">
      <transaction-type code="2" />
      <transaction-date iso-date="2024-12-05" />
      <value currency="USD" value-date="2024-12-05">2543781.00</value>
      <description>
        <narrative>Global Fund commitment to ETH-Z-UNICEFP01.</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="40">
        <narrative>United Nations Children's Fund</narrative>
      </receiver-org>
    </transaction>
    <transaction ref="1558401b-e263-4b69-9142-ae93b77427b7">
      <transaction-type code="3" />
      <transaction-date iso-date="2024-12-12" />
      <value currency="USD" value-date="2024-12-12">2543781.00</value>
      <description>
        <narrative>Global Fund disbursement to ETH-Z-UNICEFP01 (Multilateral).</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="40">
        <narrative>United Nations Children's Fund</narrative>
      </receiver-org>
      <disbursement-channel code="2" />
    </transaction>
    <transaction ref="ETH-Z-UNICEFP01-EXP-20250331">
      <transaction-type code="4" />
      <transaction-date iso-date="2025-03-31" />
      <value currency="USD" value-date="2025-03-31">1981863.00</value>
      <description>
        <narrative>Expenditure reported by United Nations Children's Fund for ETH-Z-UNICEFP01, Oct 2024 to Mar 2025.</narrative>
      </description>
      <provider-org type="40">
        <narrative>United Nations Children's Fund</narrative>
      </provider-org>
    </transaction>
    <document-link url="https://data.theglobalfund.org/grant/ETH-Z-UNICEF" format="text/html">
      <title>
        <narrative>Grant page on the data explorer of the Global Fund.</narrative>
      </title>
      <description>
        <narrative>An overview of a grant over its lifetime.</narrative>
      </description>
      <category code="A12" />
      <category code="A01" />
      <category code="A02" />
      <category code="A05" />
      <category code="A07" />
      <category code="A08" />
      <language code="en" />
      <document-date iso-date="2026-11-11" />
    </document-link>
    <document-link url="https://www.theglobalfund.org/media/13342/core_grantregulationsversiontwo_regulations_en.pdf" format="application/pdf">
      <title>
        <narrative>Grant terms and conditions.</narrative>
      </title>
      <description>
        <narrative>General terms and conditions which apply to Global Fund grants.</narrative>
      </description>
      <category code="A04" />
      <language code="en" />
    </document-link>
    <document-link url="https://docs.theglobalfund.org/files/Applications/Funding Requests/ETH/2023/TB_HIV/en/ETH-C_FundingRequest_1_en.zip" format="application/zip">
      <title>
        <narrative>2023 - Funding Request - Window 3 - TB/HIV - Ethiopia - English</narrative>
      </title>
      <description>
        <narrative>Funding Request of funding request FR1619-ETH-C.</narrative>
      </description>
      <category code="A01" />
      <category code="A02" />
      <category code="A08" />
      <language code="en" />
      <document-date iso-date="2023-08-21" />
    </document-link>
    <document-link url="https://docs.theglobalfund.org/files/Applications/Funding Requests/ETH/2023/Malaria/en/ETH-M_FundingRequest_1_en.zip" format="application/zip">
      <title>
        <narrative>2023 - Funding Request - Window 3 - Malaria - Ethiopia - English</narrative>
      </title>
      <description>
        <narrative>Funding Request of funding request FR1620-ETH-M.</narrative>
      </description>
      <category code="A01" />
      <category code="A02" />
      <category code="A08" />
      <language code="en" />
      <document-date iso-date="2023-08-21" />
    </document-link>
    <conditions attached="1">
      <condition type="1">
        <narrative>1 - Personal Data (1) Principles. The Principal Recipient, acknowledges that Program Activities are expected to respect the following principles and rights (“Data Protection Principles”): (a) Information that could be used to identify a natural person (“Personal Data”) will be: (i) processed lawfully, fairly and transparently; (ii) collected for specified, explicit and legitimate purposes and not further processed in a manner not compatible with those purposes;  (iii) adequate, relevant and limited to what is necessary for the purposes for which they are processed; (iv) accurate and, where necessary, kept up to date; (v) kept in a form which permits identification of the individuals for no longer than is necessary for the purposes for which the Personal Data is processed; and (vi) processed in a manner that ensures appropriate security of the Personal Data; and (b) Natural persons are afforded, where relevant, the right to information about Personal Data that is processed; the right to access and rectify or erase Personal Data; the right to data portability; the right to confidentiality of electronic communications; and the right to object to processing. (2) Limitations. Where collection and processing of Personal Data is required in order to implement Program Activities, whether by the Principal Recipient, a Sub-recipient, or Supplier, the Principal Recipient should respect the Data Protection Principles: (a) to the extent that doing so does not violate or conflict with applicable law and/or policy; and (b) subject to the Principal Recipient balancing the Data Protection Principles with other fundamental rights in accordance with the principle of proportionality, taking into account the risks to the rights and freedoms of natural persons.</narrative>
      </condition>
      <condition type="1">
        <narrative>2 - With respect to Section 7.6 (Right of Access) of the Global Fund Grant Regulations (as amended from time to time), (1) the Global Fund may collect or seek to collect data, and it is possible that such data may contain Personal Data, and (2), prior to collection and at all times thereafter, the Principal Recipient shall take all necessary actions to ensure that the transfer of such information to the Global Fund does not violate any applicable law or regulation.</narrative>
      </condition>
      <condition type="2">
        <narrative>3 - Unless otherwise notified by the Global Fund in writing, prior to the use of Grant Funds to finance the procurement of second-line anti-tuberculosis drugs and for each disbursement request that includes funds for the procurement of multi-drug resistant tuberculosis medicines, the Principal Recipient shall submit to the Global Fund and obtain the Global Fund’s written approval of a written confirmation of the price estimate and quantities of the second-line anti-tuberculosis drugs that will be procured by the Principal Recipient from the Global Drug Facility’s procurement agent.</narrative>
      </condition>
      <condition type="1">
        <narrative>4 - UNICEF shall reasonably ensure that Grant Funds are not used by UNICEF in contravention of any applicable sanctions prohibiting or materially restricting the disbursement and/or use of Grant Funds or, implementation of Program Activities (collectively, “Applicable Sanctions”), and promptly notify the Global Fund of any material due diligence findings inconsistent with and/or in contravention of Applicable Sanctions. Prior to UNICEF transacting with any counterparty in connection with a Global Fund-financed program, and thereafter, UNICEF shall conduct reasonable due diligence and ensure, including through the inclusion and enforcement of contractual obligations, that any Sub-recipient and supplier shall: (a) reasonably ensure that no Grant Funds are used or disbursed in contravention of any Applicable Sanctions; (b) provide prompt notice to UNICEF and the Global Fund of any material due diligence findings inconsistent with and/or in contravention of Applicable Sanctions; and (c) ensure that the same undertaking is included in any downstream contracts with Sub-sub-recipients and/or suppliers.</narrative>
      </condition>
      <condition type="2">
        <narrative>5 - (1) The Global Fund and UNICEF agree that it is important to take all necessary precautions to prevent conflicts of interest and prohibited practices, sexual exploitation, abuse and harassment (“SEAH”) and to protect children’s rights. To this end, the Parties acknowledge and agree that, in the performance of its activities in connection with Global Fund-financed programs, UNICEF shall use, and shall cause Sub-recipients and suppliers to maintain, standards of conduct in accordance with UNICEF’s regulations, rules, procedures, policies and administrative directives and instructions (“UNICEF’s Regulatory Framework”). For the avoidance of doubt, the parties agree that: a. this section 5.5, is without prejudice to the Global Fund’s rights or remedies under the Framework Agreement, including, without limitation, the requirements defined at sections 7.7(2) and 7.7(4) of the Global Fund’s Grant Regulations (2014), as amended by the Framework Agreement, which are applicable to allegations relating to SEAH, child protection, conflicts of interests and prohibited practices; b. “sexual harassment” as defined in UNICEF’s Regulatory Framework applies to conduct in connection with Global-Fund financed programs; and c. with respect to any allegation of SEAH occurring in connection with Global Fund-financed programs, UNICEF shall apply, and shall cause Sub-recipients and suppliers to apply, the principles and practices set out in the UNICEF Strategy to Prevent and Respond to Sexual Exploitation and Abuse and Sexual Harassment (January 2019) and shall: (i) facilitate and/or provide assistance to victims and survivors related to their safety and protection, medical care, psychosocial support and legal services; and (ii) facilitate victim and survivors’ timely, safe access to a remedy and/or resolution. (2) It is the understanding of the Parties that the standards of conduct reflected in UNICEF’s Regulatory Framework on conflicts of interest, prohibited practices, SEAH and protection of children’s right, as listed in Annex 1, are (and shall continue to be) consistent in all material respects with the provisions on SEAH, child protection and conflicts of interest of the Global Fund’s Codes of Conduct for Recipients of Global Fund Resources and/or Suppliers as well as with the prohibited practices of the Global Fund’s Policy to Combat Fraud and Corruption (together, the “Global Fund’s Codes of Conduct and PCFC”) with respect to all funded activities. UNICEF represents that Sub-recipients and/or supplier agreements take into account the principles reflected in UNICEF’s Regulatory Framework on conflicts of interest, prohibited practices, SEAH and protection of children’s rights, as listed in Annex 1. (3) Each Party will promptly inform the other in writing of any amendments, replacements or expansions made to the Global Fund’s Codes of Conduct and PCFC and the UNICEF documents listed in Annex 1. In the event that any such amendments, replacements or expansions give rise to a potential or actual inconsistency (including with respect to those standards maintained by any Sub-recipient or supplier), within 30 calendar days after such notification, UNICEF and the Global Fund agree to discuss in good faith any amendments that may be required to this section, and if the Parties fail to reach agreement within such time, either Party may terminate or suspend this Grant Agreement (in whole or in part) in accordance with Section 10.2 of the Global Fund Grant Regulations (as amended from time to time) (as amended by the Framework Agreement).</narrative>
      </condition>
    </conditions>
    <result type="1" aggregation-status="0">
      <title>
        <narrative>Proportion of confirmed malaria cases that received first-line antimalarial treatment at public sector health facilities</narrative>
      </title>
      <description>
        <narrative>Module: Case management.</narrative>
      </description>
      <indicator measure="2" aggregation-status="0">
        <title>
          <narrative>Proportion of confirmed malaria cases that received first-line antimalarial treatment at public sector health facilities</narrative>
        </title>
        <description>
          <narrative>Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative.</narrative>
        </description>
        <baseline year="2024" iso-date="2024-12-31" value="100">
          <comment>
            <narrative>Numerator: 53520; Denominator: 53520.</narrative>
          </comment>
        </baseline>
        <baseline year="2024" iso-date="2024-12-31" value="100">
          <dimension name="Age" value="5+" />
          <comment>
            <narrative>Numerator: 44956; Denominator: 44956.</narrative>
          </comment>
        </baseline>
        <baseline year="2024" iso-date="2024-12-31" value="100">
          <dimension name="Age" value="&lt;5" />
          <comment>
            <narrative>Numerator: 8563; Denominator: 8563.</narrative>
          </comment>
        </baseline>
        <period>
          <period-start iso-date="2024-10-01" />
          <period-end iso-date="2025-03-31" />
          <target value="29.91">
            <comment>
              <narrative>Numerator: 8005; Denominator: 26760.</narrative>
            </comment>
          </target>
        </period>
        <period>
          <period-start iso-date="2025-04-01" />
          <period-end iso-date="2025-09-30" />
          <target value="29.91">
            <comment>
              <narrative>Numerator: 8005; Denominator: 26760.</narrative>
            </comment>
          </target>
          <actual value="100">
            <comment>
              <narrative>Numerator: 66117; Denominator: 66117.</narrative>
            </comment>
          </actual>
          <actual value="100">
            <dimension name="Age" value="5+" />
            <comment>
              <narrative>Numerator: 73946; Denominator: 73946.</narrative>
            </comment>
          </actual>
          <actual value="100">
            <dimension name="Age" value="&lt;5" />
            <comment>
              <narrative>Numerator: 10360; Denominator: 10360.</narrative>
            </comment>
          </actual>
        </period>
      </indicator>
    </result>
    <result type="1" aggregation-status="0">
      <title>
        <narrative>Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities</narrative>
      </title>
      <description>
        <narrative>Module: Case management.</narrative>
      </description>
      <indicator measure="2" aggregation-status="0">
        <title>
          <narrative>Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities</narrative>
        </title>
        <description>
          <narrative>Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative.</narrative>
        </description>
        <baseline year="2024" iso-date="2024-12-31" value="63">
          <comment>
            <narrative>Numerator: 218969; Denominator: 347570.</narrative>
          </comment>
        </baseline>
        <baseline year="2024" iso-date="2024-12-31" value="63">
          <dimension name="Age" value="5+" />
          <comment>
            <narrative>Numerator: 183934; Denominator: 291959.</narrative>
          </comment>
        </baseline>
        <period>
          <period-start iso-date="2024-10-01" />
          <period-end iso-date="2025-03-31" />
          <target value="38.25">
            <comment>
              <narrative>Numerator: 93061; Denominator: 243299.</narrative>
            </comment>
          </target>
        </period>
        <period>
          <period-start iso-date="2025-04-01" />
          <period-end iso-date="2025-09-30" />
          <target value="76.5">
            <comment>
              <narrative>Numerator: 186123; Denominator: 243299.</narrative>
            </comment>
          </target>
          <actual value="97.71">
            <comment>
              <narrative>Numerator: 189343; Denominator: 193780.</narrative>
            </comment>
          </actual>
          <actual value="98.2">
            <dimension name="Age" value="5+" />
            <comment>
              <narrative>Numerator: 205927; Denominator: 209712.</narrative>
            </comment>
          </actual>
        </period>
      </indicator>
    </result>
    <result type="1" aggregation-status="0">
      <title>
        <narrative>Number of people with confirmed RR-TB and/or MDR-TB notified</narrative>
      </title>
      <description>
        <narrative>Module: Drug-resistant (DR)-TB diagnosis, treatment and care.</narrative>
      </description>
      <indicator measure="5" aggregation-status="0">
        <title>
          <narrative>Number of people with confirmed RR-TB and/or MDR-TB notified</narrative>
        </title>
        <description>
          <narrative>Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative.</narrative>
        </description>
        <baseline year="2024" iso-date="2024-12-31">
          <comment>
            <narrative>Numerator: 6.</narrative>
          </comment>
        </baseline>
        <baseline year="2024" iso-date="2024-12-31">
          <dimension name="Age" value="&lt;15" />
          <comment>
            <narrative>Numerator: 1; Denominator: 6; Percentage: 16.67%.</narrative>
          </comment>
        </baseline>
        <baseline year="2024" iso-date="2024-12-31">
          <dimension name="Gender" value="Female" />
          <comment>
            <narrative>Numerator: 1; Denominator: 6; Percentage: 16.67%.</narrative>
          </comment>
        </baseline>
        <baseline year="2024" iso-date="2024-12-31">
          <dimension name="Gender" value="Male" />
          <comment>
            <narrative>Numerator: 5; Denominator: 6; Percentage: 83.33%.</narrative>
          </comment>
        </baseline>
        <baseline year="2024" iso-date="2024-12-31">
          <dimension name="HIV status" value="Negative" />
          <comment>
            <narrative>Numerator: 5; Denominator: 6; Percentage: 83.33%.</narrative>
          </comment>
        </baseline>
        <baseline year="2024" iso-date="2024-12-31">
          <dimension name="HIV status" value="Positive" />
          <comment>
            <narrative>Numerator: 1; Denominator: 6; Percentage: 16.67%.</narrative>
          </comment>
        </baseline>
        <period>
          <period-start iso-date="2024-10-01" />
          <period-end iso-date="2025-03-31" />
          <target>
            <comment>
              <narrative>Numerator: 3.</narrative>
            </comment>
          </target>
        </period>
        <period>
          <period-start iso-date="2025-04-01" />
          <period-end iso-date="2025-09-30" />
          <target>
            <comment>
              <narrative>Numerator: 7.</narrative>
            </comment>
          </target>
          <actual>
            <comment>
              <narrative>Numerator: 3.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="Age" value="&lt;15" />
            <comment>
              <narrative>Numerator: 0.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="Gender" value="Female" />
            <comment>
              <narrative>Numerator: 0.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="Gender" value="Male" />
            <comment>
              <narrative>Numerator: 3.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="HIV status" value="Negative" />
            <comment>
              <narrative>Numerator: 3.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="HIV status" value="Positive" />
            <comment>
              <narrative>Numerator: 0.</narrative>
            </comment>
          </actual>
        </period>
      </indicator>
    </result>
    <result type="1" aggregation-status="0">
      <title>
        <narrative>Number of patients with of all forms of TB notified (i.e., bacteriologically confirmed + clinically diagnosed); *includes only those with new and relapse TB</narrative>
      </title>
      <description>
        <narrative>Module: TB diagnosis, treatment and care.</narrative>
      </description>
      <indicator measure="5" aggregation-status="0">
        <title>
          <narrative>Number of patients with of all forms of TB notified (i.e., bacteriologically confirmed + clinically diagnosed); *includes only those with new and relapse TB</narrative>
        </title>
        <description>
          <narrative>Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative.</narrative>
        </description>
        <baseline year="2024" iso-date="2024-12-31">
          <comment>
            <narrative>Numerator: 360.</narrative>
          </comment>
        </baseline>
        <baseline year="2024" iso-date="2024-12-31">
          <dimension name="Age" value="15+" />
          <comment>
            <narrative>Numerator: 315; Denominator: 360; Percentage: 87.5%.</narrative>
          </comment>
        </baseline>
        <baseline year="2025" iso-date="2025-12-31">
          <dimension name="Gender" value="Male" />
          <comment>
            <narrative>Numerator: 216; Denominator: 360; Percentage: 60%.</narrative>
          </comment>
        </baseline>
        <baseline year="2026" iso-date="2026-12-31">
          <dimension name="HIV status" value="Negative" />
          <comment>
            <narrative>Numerator: 328; Denominator: 360; Percentage: 91.11%.</narrative>
          </comment>
        </baseline>
        <baseline year="2027" iso-date="2027-12-31">
          <dimension name="Type of TB" value="Bacteriologically confirmed" />
          <comment>
            <narrative>Numerator: 92; Denominator: 360; Percentage: 25.56%.</narrative>
          </comment>
        </baseline>
        <baseline year="2028" iso-date="2028-12-31">
          <dimension name="Gender" value="Female" />
          <comment>
            <narrative>Numerator: 144; Denominator: 360; Percentage: 40%.</narrative>
          </comment>
        </baseline>
        <baseline year="2029" iso-date="2029-12-31">
          <dimension name="HIV status" value="Positive" />
          <comment>
            <narrative>Numerator: 32; Denominator: 360; Percentage: 8.89%.</narrative>
          </comment>
        </baseline>
        <period>
          <period-start iso-date="2024-10-01" />
          <period-end iso-date="2025-03-31" />
          <target>
            <comment>
              <narrative>Numerator: 189.</narrative>
            </comment>
          </target>
        </period>
        <period>
          <period-start iso-date="2025-04-01" />
          <period-end iso-date="2025-09-30" />
          <target>
            <comment>
              <narrative>Numerator: 315.</narrative>
            </comment>
          </target>
          <actual>
            <comment>
              <narrative>Numerator: 347.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="Age" value="15+" />
            <comment>
              <narrative>Numerator: 218.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="Type of TB" value="Bacteriologically confirmed" />
            <comment>
              <narrative>Numerator: 222.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="Gender" value="Female" />
            <comment>
              <narrative>Numerator: 97.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="Gender" value="Male" />
            <comment>
              <narrative>Numerator: 144.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="HIV status" value="Negative" />
            <comment>
              <narrative>Numerator: 227.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="HIV status" value="Positive" />
            <comment>
              <narrative>Numerator: 9.</narrative>
            </comment>
          </actual>
        </period>
      </indicator>
    </result>
    <result type="1" aggregation-status="0">
      <title>
        <narrative>Percentage of new and relapse TB patients tested using WHO recommended rapid diagnostic tests at the time of diagnosis</narrative>
      </title>
      <description>
        <narrative>Module: TB diagnosis, treatment and care.</narrative>
      </description>
      <indicator measure="5" aggregation-status="0">
        <title>
          <narrative>Percentage of new and relapse TB patients tested using WHO recommended rapid diagnostic tests at the time of diagnosis</narrative>
        </title>
        <description>
          <narrative>Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative.</narrative>
        </description>
        <baseline year="2024" iso-date="2024-12-31">
          <comment>
            <narrative>Numerator: 103; Denominator: 360; Percentage: 28.61%.</narrative>
          </comment>
        </baseline>
        <baseline year="2024" iso-date="2024-12-31">
          <dimension name="Provider type" value="Public" />
          <comment>
            <narrative>Numerator: 103; Denominator: 360; Percentage: 28.61%.</narrative>
          </comment>
        </baseline>
        <period>
          <period-start iso-date="2024-10-01" />
          <period-end iso-date="2025-03-31" />
          <target>
            <comment>
              <narrative>Numerator: 57; Denominator: 189; Percentage: 30.16%.</narrative>
            </comment>
          </target>
        </period>
        <period>
          <period-start iso-date="2025-04-01" />
          <period-end iso-date="2025-09-30" />
          <target>
            <comment>
              <narrative>Numerator: 189; Denominator: 315; Percentage: 60%.</narrative>
            </comment>
          </target>
          <actual>
            <comment>
              <narrative>Numerator: 162; Denominator: 289; Percentage: 56.06%.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="Provider type" value="Public" />
            <comment>
              <narrative>Numerator: 222.</narrative>
            </comment>
          </actual>
        </period>
      </indicator>
    </result>
  </iati-activity>
</iati-activities>